Fortitude Family Office’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.54K Buy
58
+18
+45% +$1.23K ﹤0.01% 1126
2026
Q1
$2.58K Buy
40
+21
+111% +$1.48K ﹤0.01% 1193
2025
Q4
$1.28K Sell
19
-11
-37% -$740 ﹤0.01% 1362
2025
Q3
$2.2K Buy
30
+8
+36% +$531 ﹤0.01% 1178
2025
Q2
$1.14K Buy
+22
New +$1.25K ﹤0.01% 1444
2025
Q1
Sell
-18
Closed -$861 1215
2024
Q4
$861 Hold
18
﹤0.01% 1152
2024
Q3
$1.03K Buy
+18
New +$1.03K ﹤0.01% 1101

Other funds holding HALO

Fortitude Family Office's HALO Position: Q2 2026 in Review

Fortitude Family Office increased its Halozyme (HALO) stake by 45% in Q2 2026, buying an estimated $1.23K and bringing the position to 58 shares worth $4.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Fortitude Family Office first reported a position in HALO in Q3 2024 and has held it in 7 quarters since. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Fortitude Family Office held 58 shares of Halozyme worth $4.54K as of Q2 2026.
  • Fortitude Family Office bought 18 Halozyme shares in Q2 2026, an estimated $1.23K.
  • Halozyme made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1126 holding.
  • Fortitude Family Office first reported a position in Halozyme in Q3 2024 and has held it in 7 quarters since.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.